The Impact of COVID-19 on Pediatric Malignancy Diagnosis and Treatment: Never the Same but Lessons Learned.
Ghadir K KatatoPrasiksha SitaulaAvanti GupteEman T Al-AntaryPublished in: Vaccines (2023)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic affected the pediatric oncology population globally. Over the course of 2 years, increasing reports have been made to better understand this entity and its pathologic complications on these patients. The pandemic has allowed healthcare providers, hospital systems, and leading oncologic societies to quickly adapt and formulate new guidelines for the effective understanding, management, and treatment of patients with pediatric malignancy.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- healthcare
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- prognostic factors
- ejection fraction
- neoadjuvant chemotherapy
- palliative care
- rectal cancer
- emergency department
- risk factors
- adverse drug
- young adults
- health insurance
- combination therapy
- childhood cancer